P&K Skin Research Center Co. Ltd
P&K Skin Research Center Co., Ltd. engages in the evaluation and research of dermatological products in South Korea. It provides scientific information and technical support services for new cosmetic raw material development, functional cosmetics, and human application testing of quasi-drugs. The company performs human application, safety, efficacy, cosmeceuticals, health food, sensory, and in vi… Read more
P&K Skin Research Center Co. Ltd (347740) - Total Assets
Latest total assets as of September 2025: ₩85.87 Billion KRW
Based on the latest financial reports, P&K Skin Research Center Co. Ltd (347740) holds total assets worth ₩85.87 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
P&K Skin Research Center Co. Ltd - Total Assets Trend (2018–2024)
This chart illustrates how P&K Skin Research Center Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
P&K Skin Research Center Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
P&K Skin Research Center Co. Ltd's total assets of ₩85.87 Billion consist of 58.7% current assets and 41.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩6.46 Billion | 7.9% |
| Accounts Receivable | ₩1.37 Billion | 1.7% |
| Inventory | ₩0.00 | 0.0% |
| Property, Plant & Equipment | ₩3.64 Billion | 4.4% |
| Intangible Assets | ₩198.35 Million | 0.2% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how P&K Skin Research Center Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: P&K Skin Research Center Co. Ltd's current assets represent 58.7% of total assets in 2024, a decrease from 71.0% in 2018.
- Cash Position: Cash and equivalents constituted 7.9% of total assets in 2024, up from 0.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is cash and equivalents at 7.9% of total assets.
P&K Skin Research Center Co. Ltd Competitors by Total Assets
Key competitors of P&K Skin Research Center Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.17 Billion |
|
SMO ClinPlus Co. Ltd.
SHE:301257
|
China | CN¥1.47 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
P&K Skin Research Center Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - P&K Skin Research Center Co. Ltd generates 0.22x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, P&K Skin Research Center Co. Ltd generates $7.09 in net profit.
P&K Skin Research Center Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.91 | 12.46 | 14.38 |
| Quick Ratio | 13.91 | 12.46 | 14.38 |
| Cash Ratio | 0.00 | 1.86 | 0.00 |
| Working Capital | ₩44.27 Billion | ₩ 47.95 Billion | ₩ 47.69 Billion |
P&K Skin Research Center Co. Ltd - Advanced Valuation Insights
This section examines the relationship between P&K Skin Research Center Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.85 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 6.0% |
| Total Assets | ₩82.04 Billion |
| Market Capitalization | $15.85 Million USD |
Valuation Analysis
Below Book Valuation: The market values P&K Skin Research Center Co. Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: P&K Skin Research Center Co. Ltd's assets grew by 6.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for P&K Skin Research Center Co. Ltd (2018–2024)
The table below shows the annual total assets of P&K Skin Research Center Co. Ltd from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩82.04 Billion | +5.98% |
| 2023-12-31 | ₩77.41 Billion | +3.85% |
| 2022-12-31 | ₩74.54 Billion | +11.10% |
| 2021-12-31 | ₩67.09 Billion | +12.02% |
| 2020-12-31 | ₩59.89 Billion | +114.14% |
| 2019-12-31 | ₩27.97 Billion | +58.55% |
| 2018-12-31 | ₩17.64 Billion | -- |